Literature DB >> 16610246

Paraadrenal Castleman disease presenting with adrenal hyperandrogenism.

K Müssig1, B Gallwitz, F Machicao, M Horger, H-U Häring, E Kaiserling.   

Abstract

Castleman disease, or angiofollicular lymph node hyperplasia, is a rare benign lymphoproliferative disorder. We report an uncommon case of retroperitoneal Castleman syndrome associated with adrenal hyperandrogenism and with interleukin-6 as the possible link in the pathophysiology of both disturbances. Four years after surgical resection of the paraadrenal mass, the patient is free of signs of recurrence of Castleman disease and adrenal hyperandrogenism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16610246     DOI: 10.1007/BF03344093

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  24 in total

1.  Castleman disease: CT and MR imaging features of a retroperitoneal location in association with paraneoplastic pemphigus.

Authors:  M Irsutti; J L Paul; J Selves; J J Railhac
Journal:  Eur Radiol       Date:  1999       Impact factor: 5.315

2.  Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure.

Authors:  C Tsigos; D A Papanicolaou; R Defensor; C S Mitsiadis; I Kyrou; G P Chrousos
Journal:  Neuroendocrinology       Date:  1997-07       Impact factor: 4.914

3.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

4.  Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency?

Authors:  D A Papanicolaou; C Tsigos; E H Oldfield; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  1996-06       Impact factor: 5.958

Review 5.  Multicentric Castleman's disease.

Authors:  B A Peterson; G Frizzera
Journal:  Semin Oncol       Date:  1993-12       Impact factor: 4.929

6.  Interleukin-6 and ACTH act synergistically to stimulate the release of corticosterone from adrenal gland cells.

Authors:  M A Salas; S W Evans; M J Levell; J T Whicher
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

7.  Interleukin-6 gene expression in Castleman's disease.

Authors:  M B Leger-Ravet; M Peuchmaur; O Devergne; J Audouin; M Raphael; J Van Damme; P Galanaud; J Diebold; D Emilie
Journal:  Blood       Date:  1991-12-01       Impact factor: 22.113

8.  The effect of interleukin-6 on pituitary hormone release in vivo and in vitro.

Authors:  K Lyson; S M McCann
Journal:  Neuroendocrinology       Date:  1991-09       Impact factor: 4.914

9.  Androgen binding capacity and 5 alpha-reductase activity in pubic skin fibroblasts from hirsute patients.

Authors:  I Mowszowicz; E Melanitou; A Doukani; F Wright; F Kuttenn; P Mauvais-Jarvis
Journal:  J Clin Endocrinol Metab       Date:  1983-06       Impact factor: 5.958

10.  Case report: Castleman disease in association with POEMS.

Authors:  H M Adelman; M L Cacciatore; J F Pascual; J M Mike; W M Alberts; P M Wallach
Journal:  Am J Med Sci       Date:  1994-02       Impact factor: 2.378

View more
  1 in total

1.  Two Cases of Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome with High Serum Procalcitonin Levels, Including the First Case Complicated with Adrenal Hemorrhaging.

Authors:  Mizuho Nara; Atsushi Komatsuda; Fumiko Itoh; Hajime Kaga; Masaya Saitoh; Masaru Togashi; Yoshihiro Kameoka; Hideki Wakui; Naoto Takahashi
Journal:  Intern Med       Date:  2017-05-15       Impact factor: 1.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.